Serum levels of matrix metalloproteinase 2 in patients with breast cancer

Shyr Ming Sheen-Chen, Han Shiang Chen, Hock Liew Eng, Chih Chi Sheen, Wei Jen Chen

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Matrix metalloproteinases (MMPs) have been reported to be associated with invasive and metastatic behaviors of human malignant tumors. However, there is still limited knowledge about the role of matrix metalloproteinases-2 (MMP-2) in breast cancer. This study was designed with the aim to elucidate the possible relationship between the preoperative circulating MMP-2 and breast cancer. Fifty-seven consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumor (six with fibrocystic disease and six with fibroadenoma). Serum concentrations of MMP-2 were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor stage, age, estrogen receptor, lymph node status, and TNM staging were reviewed and recorded. The mean value of serum MMP-2 in patients with invasive breast cancer was 694.3±140.5 ng/ml and those of control group were 593.3±134.0 ng/ml and the difference was significant (P=0.026). Furthermore, there were significantly higher serum levels of MMP-2 in the patients with more advanced primary tumor staging (P=0.005), in the patients with more advanced lymph node status (P=0.011) and in the patients with more advanced TNM staging (P<0.001). In multivariate analysis, TNM staging (P<0.001) appeared as independent factor regarding the significant higher serum levels of MMP-2. Patients with more advanced TNM staging were shown to have higher serum MMP-2 levels. Thus preoperative serum MMP-2 levels might reflect the severity of invasive breast cancer and deserve further evaluation.

Original languageEnglish
Pages (from-to)79-82
Number of pages4
JournalCancer Letters
Volume173
Issue number1
DOIs
Publication statusPublished - Oct 8 2001
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 2
Neoplasm Staging
Breast Neoplasms
Serum
Lymph Nodes
Fibroadenoma
Control Groups
Matrix Metalloproteinases
Immunoenzyme Techniques
Centrifugation
Estrogen Receptors
Neoplasms
Multivariate Analysis

Keywords

  • Breast cancer
  • Extracellular matrix
  • Gelatinase A
  • IV collagen
  • Matrix metalloproteinases-2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum levels of matrix metalloproteinase 2 in patients with breast cancer. / Sheen-Chen, Shyr Ming; Chen, Han Shiang; Eng, Hock Liew; Sheen, Chih Chi; Chen, Wei Jen.

In: Cancer Letters, Vol. 173, No. 1, 08.10.2001, p. 79-82.

Research output: Contribution to journalArticle

Sheen-Chen, Shyr Ming ; Chen, Han Shiang ; Eng, Hock Liew ; Sheen, Chih Chi ; Chen, Wei Jen. / Serum levels of matrix metalloproteinase 2 in patients with breast cancer. In: Cancer Letters. 2001 ; Vol. 173, No. 1. pp. 79-82.
@article{f7094002ba2449e4b7f3a3c65ff380f3,
title = "Serum levels of matrix metalloproteinase 2 in patients with breast cancer",
abstract = "Matrix metalloproteinases (MMPs) have been reported to be associated with invasive and metastatic behaviors of human malignant tumors. However, there is still limited knowledge about the role of matrix metalloproteinases-2 (MMP-2) in breast cancer. This study was designed with the aim to elucidate the possible relationship between the preoperative circulating MMP-2 and breast cancer. Fifty-seven consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumor (six with fibrocystic disease and six with fibroadenoma). Serum concentrations of MMP-2 were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor stage, age, estrogen receptor, lymph node status, and TNM staging were reviewed and recorded. The mean value of serum MMP-2 in patients with invasive breast cancer was 694.3±140.5 ng/ml and those of control group were 593.3±134.0 ng/ml and the difference was significant (P=0.026). Furthermore, there were significantly higher serum levels of MMP-2 in the patients with more advanced primary tumor staging (P=0.005), in the patients with more advanced lymph node status (P=0.011) and in the patients with more advanced TNM staging (P<0.001). In multivariate analysis, TNM staging (P<0.001) appeared as independent factor regarding the significant higher serum levels of MMP-2. Patients with more advanced TNM staging were shown to have higher serum MMP-2 levels. Thus preoperative serum MMP-2 levels might reflect the severity of invasive breast cancer and deserve further evaluation.",
keywords = "Breast cancer, Extracellular matrix, Gelatinase A, IV collagen, Matrix metalloproteinases-2",
author = "Sheen-Chen, {Shyr Ming} and Chen, {Han Shiang} and Eng, {Hock Liew} and Sheen, {Chih Chi} and Chen, {Wei Jen}",
year = "2001",
month = "10",
day = "8",
doi = "10.1016/S0304-3835(01)00657-7",
language = "English",
volume = "173",
pages = "79--82",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Serum levels of matrix metalloproteinase 2 in patients with breast cancer

AU - Sheen-Chen, Shyr Ming

AU - Chen, Han Shiang

AU - Eng, Hock Liew

AU - Sheen, Chih Chi

AU - Chen, Wei Jen

PY - 2001/10/8

Y1 - 2001/10/8

N2 - Matrix metalloproteinases (MMPs) have been reported to be associated with invasive and metastatic behaviors of human malignant tumors. However, there is still limited knowledge about the role of matrix metalloproteinases-2 (MMP-2) in breast cancer. This study was designed with the aim to elucidate the possible relationship between the preoperative circulating MMP-2 and breast cancer. Fifty-seven consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumor (six with fibrocystic disease and six with fibroadenoma). Serum concentrations of MMP-2 were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor stage, age, estrogen receptor, lymph node status, and TNM staging were reviewed and recorded. The mean value of serum MMP-2 in patients with invasive breast cancer was 694.3±140.5 ng/ml and those of control group were 593.3±134.0 ng/ml and the difference was significant (P=0.026). Furthermore, there were significantly higher serum levels of MMP-2 in the patients with more advanced primary tumor staging (P=0.005), in the patients with more advanced lymph node status (P=0.011) and in the patients with more advanced TNM staging (P<0.001). In multivariate analysis, TNM staging (P<0.001) appeared as independent factor regarding the significant higher serum levels of MMP-2. Patients with more advanced TNM staging were shown to have higher serum MMP-2 levels. Thus preoperative serum MMP-2 levels might reflect the severity of invasive breast cancer and deserve further evaluation.

AB - Matrix metalloproteinases (MMPs) have been reported to be associated with invasive and metastatic behaviors of human malignant tumors. However, there is still limited knowledge about the role of matrix metalloproteinases-2 (MMP-2) in breast cancer. This study was designed with the aim to elucidate the possible relationship between the preoperative circulating MMP-2 and breast cancer. Fifty-seven consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumor (six with fibrocystic disease and six with fibroadenoma). Serum concentrations of MMP-2 were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor stage, age, estrogen receptor, lymph node status, and TNM staging were reviewed and recorded. The mean value of serum MMP-2 in patients with invasive breast cancer was 694.3±140.5 ng/ml and those of control group were 593.3±134.0 ng/ml and the difference was significant (P=0.026). Furthermore, there were significantly higher serum levels of MMP-2 in the patients with more advanced primary tumor staging (P=0.005), in the patients with more advanced lymph node status (P=0.011) and in the patients with more advanced TNM staging (P<0.001). In multivariate analysis, TNM staging (P<0.001) appeared as independent factor regarding the significant higher serum levels of MMP-2. Patients with more advanced TNM staging were shown to have higher serum MMP-2 levels. Thus preoperative serum MMP-2 levels might reflect the severity of invasive breast cancer and deserve further evaluation.

KW - Breast cancer

KW - Extracellular matrix

KW - Gelatinase A

KW - IV collagen

KW - Matrix metalloproteinases-2

UR - http://www.scopus.com/inward/record.url?scp=0035829010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035829010&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(01)00657-7

DO - 10.1016/S0304-3835(01)00657-7

M3 - Article

C2 - 11578812

AN - SCOPUS:0035829010

VL - 173

SP - 79

EP - 82

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -